Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism

JCI Insight

Volumn 1, Issue 6, 2016, Pages

  Sood, Anup ^a   Miller, Alexandra M ^b   Brogi, Edi ^b   Sui, Yunxia ^a   Armenia, Joshua ^b   McDonough, Elizabeth ^a   Santamaria Pang, Alberto ^a   Carlin, Sean ^b   Stamper, Aleksandra ^b   Campos, Carl ^b   Pang, Zhengyu ^a   Li, Qing ^a   Port, Elisa ^b   Graeber, Thomas G ^c   Schultz, Nikolaus ^b   Ginty, Fiona ^a   Larson, Steven M ^b   Mellinghoff, Ingo K ^b,d  

^a GE GLOBAL RESEARCH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135867990     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.87030     Document Type: Article

References (45)

1. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467):338-345.
2. Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892.
3. Gerlinger M, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46(3):225-233.
4. Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256-259.
5. Yates LR, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015; 21(7):751-759.
6. Boutros PC, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47(7):736-745.
7. Izumchenko E, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015; 6:8258.
8. Murugaesu N, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015; 5(8):821-831.
9. Alizadeh AA, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015; 21(8):846-853.
10. Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015; 15(8):473-483.
11. Angelo M, et al. Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014; 20(4):436-442.
12. Giesen C, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014; 11(4):417-422.
13. Wang HA, et al. Fast chemical imaging at high spatial resolution by laser ablation inductively coupled plasma mass spectrometry. Anal Chem. 2013; 85(21):10107-10116.
14. Rimm DL. Next-gen immunohistochemistry. Nat Methods. 2014; 11(4):381-383.
15. Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest. 2015; 95(4):385-396.
16. Schubert W, et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol. 2006; 24(10):1270-1278.
17. Gerdes MJ, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A. 2013; 110(29):11982-11987.
18. Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7):1851-1863.
19. Hammond ME, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7):e48-e72.
20. Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015; 12(7):381-394.
21. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003; 52(1):91-118.
22. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-1573.
23. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752.
24. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst. 2014; 106(8):dju165.
25. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
26. Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-404.
27. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-1167.
28. Ahn SG, et al. Standardized uptake value of (1)(8)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. Breast Cancer Res. 2014; 16(6):502.
29. Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell. 2014; 56(4):595-607.
30. Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med. 2004; 45(6):930-932.
31. Cuzick J, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011; 29(32):4273-4278.
32. Levenson RM, Mansfield JR. Multispectral imaging in biology and medicine: slices of life. Cytometry A. 2006; 69(8):748-758.
33. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8(11):1323-1327.
34. Levenson RM, Borowsky AD, Angelo M. Immunohistochemistry and mass spectrometry for highly multiplexed cellular molecular imaging. Lab Invest. 2015; 95(4):397-405.
35. Tyanova S, Albrechtsen R, Kronqvist P, Cox J, Mann M, Geiger T. Proteomic maps of breast cancer subtypes. Nat Commun. 2016; 7:10259.
36. Geyer FC, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010; 220(5):562-573.
37. Navin N, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010; 20(1):68-80.
38. Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011; 472(7341):90-94.
39. Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015; 525(7568):261-264.
40. Janiszewska M, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015; 47(10):1212-1219.
41. Basu S, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008; 112(5):995-1000.
42. Palaskas N, et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011; 71(15):5164-5174.
43. Gregorian C, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A. 2009; 106(46):19479-19484.
44. Garcia-Cao I, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012; 149(1):49-62.
45. Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. 2008; 40(1):102-107.